Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance.

Hakooz N, Ito K, Rawden H, Gill H, Lemmers L, Boobis AR, Edwards RJ, Carlile DJ, Lake BG, Houston JB.

Pharm Res. 2006 Mar;23(3):533-9. Epub 2006 Feb 28.

PMID:
16505976
3.

Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans.

Rawden HC, Carlile DJ, Tindall A, Hallifax D, Galetin A, Ito K, Houston JB.

Xenobiotica. 2005 Jun;35(6):603-25.

PMID:
16192111
4.

Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.

Cubitt HE, Houston JB, Galetin A.

Drug Metab Dispos. 2011 May;39(5):864-73. doi: 10.1124/dmd.110.036566. Epub 2011 Feb 8.

5.
6.

Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo.

Zhang H, Gao N, Tian X, Liu T, Fang Y, Zhou J, Wen Q, Xu B, Qi B, Gao J, Li H, Jia L, Qiao H.

Sci Rep. 2015 Dec 4;5:17671. doi: 10.1038/srep17671.

7.

Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans.

Carlile DJ, Hakooz N, Bayliss MK, Houston JB.

Br J Clin Pharmacol. 1999 Jun;47(6):625-35.

9.

Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution.

Emoto C, Murayama N, Rostami-Hodjegan A, Yamazaki H.

Curr Drug Metab. 2010 Oct;11(8):678-85. Review.

PMID:
20973757
10.

Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver.

Barter ZE, Bayliss MK, Beaune PH, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, Rostami-Hodjegan A.

Curr Drug Metab. 2007 Jan;8(1):33-45. Review.

PMID:
17266522
11.

Verapamil hepatic clearance in four preclinical rat models: towards activity-based scaling.

Nicolaï J, De Bruyn T, Van Veldhoven PP, Keemink J, Augustijns P, Annaert P.

Biopharm Drug Dispos. 2015 Oct;36(7):462-80. doi: 10.1002/bdd.1959. Epub 2015 Jun 11.

PMID:
25963583
12.

Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.

Stringer RA, Strain-Damerell C, Nicklin P, Houston JB.

Drug Metab Dispos. 2009 May;37(5):1025-34. doi: 10.1124/dmd.108.024810. Epub 2009 Feb 5.

13.

Determination of microsome and hepatocyte scaling factors for in vitro/in vivo extrapolation in the rat and dog.

Smith R, Jones RD, Ballard PG, Griffiths HH.

Xenobiotica. 2008 Nov;38(11):1386-98. doi: 10.1080/00498250802491662.

PMID:
18988082
15.

Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes.

Kilford PJ, Stringer R, Sohal B, Houston JB, Galetin A.

Drug Metab Dispos. 2009 Jan;37(1):82-9. doi: 10.1124/dmd.108.023853. Epub 2008 Oct 2.

18.

Prediction of in vivo hepatic metabolic clearance of YM796 from in vitro data by use of human liver microsomes and recombinant P-450 isozymes.

Iwatsubo T, Suzuki H, Shimada N, Chiba K, Ishizaki T, Green CE, Tyson CA, Yokoi T, Kamataki T, Sugiyama Y.

J Pharmacol Exp Ther. 1997 Aug;282(2):909-19.

19.
20.

Prediction of human pharmacokinetics from preclinical information: comparative accuracy of quantitative prediction approaches.

Hosea NA, Collard WT, Cole S, Maurer TS, Fang RX, Jones H, Kakar SM, Nakai Y, Smith BJ, Webster R, Beaumont K.

J Clin Pharmacol. 2009 May;49(5):513-33. doi: 10.1177/0091270009333209. Epub 2009 Mar 19.

PMID:
19299532

Supplemental Content

Support Center